News

NRx Pharmaceuticals (NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to its intravenous ...

NRx Pharmaceuticals, Inc. (NRXP)’ NRX-100 Wins Expanded FDA Fast Track for Suicidal Depression

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. NRx Pharmaceuticals, Inc. is one of them. NRx ...
ksn.com1y

Head-to-head Trial of Prolonged-Release Oral Ketamine Formulation, KET01, and Intranasal SPRAVATO®, Finds Less Incidence of Dissociation or Cardiovascular Effects with Oral ...

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its ...
Business Wire1y

First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)

OXFORD, England--(BUSINESS WIRE)--Beckley Psytech Ltd, a private, clinical-stage biotechnology company developing rapid-acting, short-duration psychedelic medicines for neuropsychiatric conditions, ...
Nasdaq2y

Biomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression

TORONTO--(BUSINESS WIRE)-- Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...
BioWorld2y

Compass readies phase III trial of psilocybin formulation in treatment-resistant depression

Compass Pathways plc is poised to start the first ever phase III trial of the psychedelic drug psilocybin, after getting U.S. FDA backing for a study in treatment-resistant depression. The phase III, ...
TipRanks on MSN10d

NRx Pharmaceuticals (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

Austin, Texas, United States, September 3rd, 2025, FinanceWire The FDA designation expands the drug’s potential patient pool ...

Nrx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track For IV Ketamine Formulation NRX-100 In Suicidal Depression

The FDA designation expands the drug's potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually ...